- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: pediatric ependymoma.
Displaying page 1 of 1.
EudraCT Number: 2013-002766-39 | Sponsor Protocol Number: ET13-002 | Start Date*: 2021-02-17 | |||||||||||
Sponsor Name:Centre Leon Berard | |||||||||||||
Full Title: SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma | |||||||||||||
Medical condition: Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular, papillary, myxopapillary, clear-cell and tanycytic) or anaplastic ependymoma. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) IE (Ongoing) IT (Ongoing) BE (Ongoing) ES (Ongoing) NO (Ongoing) DE (Ongoing) DK (Restarted) FI (Ongoing) CZ (Ongoing) AT (Ongoing) NL (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023478-38 | Sponsor Protocol Number: OSI-774-206 | Start Date*: 2011-04-26 | |||||||||||
Sponsor Name:OSI Pharmaceuticals LLC | |||||||||||||
Full Title: Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205 | |||||||||||||
Medical condition: Recurrent or Refractory Ependymoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016836-11 | Sponsor Protocol Number: OSI-774-205 | Start Date*: 2011-04-26 | |||||||||||
Sponsor Name:OSI Pharmaceuticals LLC | |||||||||||||
Full Title: A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma | |||||||||||||
Medical condition: Recurrent or Refractory Paediatric Ependymoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004441-82 | Sponsor Protocol Number: CA209-908 | Start Date*: 2017-06-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies | |||||||||||||
Medical condition: Primary central nervous system (CNS) malignancies. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) NO (Completed) NL (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004520-10 | Sponsor Protocol Number: ACNS1021 | Start Date*: 2019-06-25 |
Sponsor Name:National Cancer Institute (NCI) | ||
Full Title: 2018-004520-10 | ||
Medical condition: Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-000854-85 | Sponsor Protocol Number: CA045-020 | Start Date*: 2021-04-19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrent or Refractory pediatric cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002931-27 | Sponsor Protocol Number: I3Y-MC-JPCS | Start Date*: 2020-10-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Rela... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002123-10 | Sponsor Protocol Number: 1200.120 | Start Date*: 2015-04-18 | ||||||||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim España, S.A. | ||||||||||||||||||||||||||||
Full Title: Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumou... | ||||||||||||||||||||||||||||
Medical condition: Paediatric patients with recurrent//refractory high grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), low grade astrocytoma, neuroblastoma, ependymoma, medulloblastoma/primitive neuroect... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) FR (Completed) DK (Completed) IT (Completed) NL (Completed) IE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000096-32 | Sponsor Protocol Number: METRO-PD1-1708 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Centre Oscar Lambret | ||||||||||||||||||||||||||||
Full Title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma | ||||||||||||||||||||||||||||
Medical condition: Progressive or refractory : • high grade glioma • neuroblastoma • other cerebral tumors • lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) BE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000127-14 | Sponsor Protocol Number: NCT-2017-0516 | Start Date*: Information not available in EudraCT |
Sponsor Name:Heidelberg University Hospital | ||
Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies | ||
Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) DE (Ongoing) NL (Ongoing) FR (Ongoing) AT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.